The Increasingly Stormy Waters of US Market Access
The US reimbursement landscape has been shifting rapidly over the last few years. We invited 31 MCO leaders to discuss the key trends.
Vocal.
The Increasingly Stormy Waters of US Market Access
Getting Asset Evaluation Right
Paying for Cell & Gene Therapy in the US: Is the Future Already Here?
New approaches to pharma sales: Success is marrying data analytics with the art of 1-1 engagement
Netflix’s revenue model as a blueprint for pharmaceutical pricing?